Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data.
Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data.
复制标题
DOI：
10.1016/j.autrev.2021.102778
复制
发表时间：
2021-04
影响因子：
13.6
通讯作者：
Mu R
中科院分区：
文献类型：
--
作者：
Xu C;Yi Z;Cai R;Chen R;Thong BY;Mu R
风湿性疾病对COVID-19感染的影响仍缺乏研究。在这里，我们进行了一项系统性综述和荟萃分析，以评估风湿性疾病患者的COVID-19结局。我们系统性检索了截至2020年8月29日的PubMed、Embase、科克伦图书馆、Scopus和预印本数据库，以查找风湿性疾病患者确诊COVID-19感染的出版物。主要结局为住院率、氧支持率、重症监护室（ICU）入住率和死亡率。使用随机效应模型进行效应量的荟萃分析，并进行荟萃回归分析以探索异质性。来自COVID-19全球流变学联盟医生登记处（COVID-19 GRA）的数据用作参考。本系统性综述和荟萃分析共纳入31篇文章，涉及1138例患者。这些出版物来自欧洲、亚洲和北美，但没有来自其他大陆的出版物。合并风湿性疾病的COVID-19感染患者的住院率、氧气支持率、ICU入住率和病死率为0.58（95%置信区间（CI）0.48-0.67）、0.33（95% CI 0.21-0.47）、0.09（95% CI 0.05-0.15）和0.07（95% CI 0.03-0.11）。欧洲的氧气支持率（0.48，95%CI 0.4-0.57）高于其他大洲。在所有住院患者中，氧支持率、ICU入住率和病死率分别为0.61（95%CI 0.48-0.73）、0.13（95%CI 0.07-0.21）和0.13（95%CI 0.09-0.18）。欧洲的病死率最高（0.19，95% CI 0.15-0.24）。尽管年龄、性别和合并症不匹配，但该荟萃分析和COVID-19 GRA的病死率（分别为7.0%和6.7%）均高于WHO数据库的病死率（3.4%）。风湿性疾病患者仍然是脆弱的，严重的结果和地理差异的显着率。迫切需要更多的研究来阐明这一人群严重结局的风险因素。
The impact of rheumatic diseases on COVID-19 infection remains poorly investigated. Here we performed a systematic review and meta-analysis to evaluate the outcomes of COVID-19 in patients with rheumatic diseases. We systematically searched PubMed, Embase, Cochrane Library, Scopus and preprint database up to 29th August 2020, for publications with confirmed COVID-19 infection in patients with rheumatic diseases. The primary outcomes were the rates of hospitalization, oxygen support, intensive care unit (ICU) admission and death. A meta-analysis of effect sizes using the random-effects models was performed, and meta-regression analyses were performed to explore heterogeneity. The data from the COVID-19 Global Rheumatology Alliance physician registry (the COVID-19 GRA) was used as a reference. A total of 31 articles involving 1138 patients were included in this systematic review and meta-analysis. The publications were from Europe, Asia and North America, but none from other continents. The overall rates of hospitalization, oxygen support, ICU admission and fatality among COVID-19 infected patients with rheumatic diseases were 0.58 (95% confidence interval (CI) 0.48–0.67), 0.33 (95% CI 0.21–0.47), 0.09 (95% CI 0.05–0.15) and 0.07 (95% CI 0.03–0.11), respectively. The rate of oxygen support in Europe (0.48, 95% CI 0.4–0.57) was higher than that in other continents. Among all hospitalized patients, the rates of oxygen support, ICU admission and fatality were 0.61 (95% CI 0.48–0.73), 0.13 (95% CI 0.07–0.21) and 0.13 (95% CI 0.09–0.18), respectively. The fatality rate was highest in Europe (0.19, 95% CI 0.15–0.24). The fatality rate was higher both in this meta-analysis and the COVID-19 GRA (7.0% and 6.7%, respectively) than that (3.4%) in WHO database, although the age, gender and comorbidity were not matched. Patients with rheumatic diseases remain vulnerable with substantial rates of severe outcomes and a geographic variation. More studies were urgently needed to elucidate the risk factors of severe outcomes in this population.
登录
查看更多内容
DOI：
10.1002/art.41450
发表时间：
2020-12
期刊：
Arthritis & rheumatology (Hoboken, N.J.)
影响因子：
--
作者：
Fernandez-Ruiz R;Masson M;Kim MY;Myers B;Haberman RH;Castillo R;Scher JU;Guttmann A;Carlucci PM;Deonaraine KK;Golpanian M;Robins K;Chang M;Belmont HM;Buyon JP;Blazer AD;Saxena A;Izmirly PM;NYU WARCOV Investigators
通讯作者：
NYU WARCOV Investigators
影响因子：
158.5
作者：
Boulware, David R.;Pullen, Matthew F.;Hullsiek, Kathy H.
通讯作者：
Hullsiek, Kathy H.
影响因子：
158.5
作者：
Cavalcanti, A. B.;Zampieri, F. G.;Berwanger, O.
通讯作者：
Berwanger, O.
95例SARS-CoV-2胃肠道症状
影响因子：
24.5
作者：
Lin, Lu;Jiang, Xiayang;Shan, Hong
通讯作者：
Shan, Hong
影响因子：
13.3
作者：
Favalli, Ennio Giulio;Monti, Sara;Montecucco, Carlomaurizio
通讯作者：
Montecucco, Carlomaurizio